non-alcoholic fatty liver disease
Conditions
Interventions
Experimental Group:The experimental group were combined with DCH+YCWL. Each dose of medicine will be prepared by the hospital's pharmacy, with the herbal solution mixed to 200 mL and vacuum-packed. I
Control Group:Oral Polyunsaturated Phosphatidylcholine Capsules (Sanofi (Beijing) Pharmaceutical Co. Ltd. National Medicine Standard H20059010 Specification: 228 mg * 24 capsules) were taken 2 capsule
Sponsors
Wuxi Huishan Traditional Chinese Medicine Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1)met the Clinical Diagnosis Criteria of NAFLD: According to the clinical diagnostic criteria recommended by the Guidelines for the Prevention and Treatment of Non-Alcoholic Fatty Liver Disease (2018 Update): No history of alcohol consumption or ethanol intake 6 months; In addition to the clinical symptoms of the primary disease symptoms such as right upper abdominal pain indigestion hepatosplenomegaly etc. may also be present; Overweight or visceral obesity and metabolic syndrome; Liver ultrasound shows findings consistent with the diagnostic criteria for diffuse fatty liver with no other causes that can explain the condition. 2 )Aged 18-70 years; 3) Liver enzyme levels do not exceed three times the upper limit of normal; 4) No use of drugs specifically targeting NAFLD in the 30 days prior to treatment
Exclusion criteria
Exclusion criteria: 1) Fatty liver caused by viral hepatitis drug-induced liver disease hepatic globus pallidus degeneration chronic alcoholism total parenteral nutrition or autoimmune liver disease; 2) Patients with a diagnosis of fatty liver based on ultrasound but without symptoms of NAFLD; 3) Pregnant or breastfeeding women; 4) Patients with cirrhosis or liver cancer; 5) Patients with severe cardiovascular cerebrovascular liver kidney hematologic or other primary diseases as well as those with psychiatric disorders; 6) Individuals with a history of allergic constitution or multiple drug allergies.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| inflammatory factors ;metabolic indicators such as glucose and lipid;liver function ; | — |
Secondary
| Measure | Time frame |
|---|---|
| adiposity index;Liver fibrosis indicators;body shape indicators ;liver stiffness LSM value; | — |
Countries
China
Contacts
Public ContactCheng Xin
Wuxi Huishan Traditional Chinese Medicine Hospital
Outcome results
None listed